# Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)

> **NCT05457699** · PHASE2 · RECRUITING · sponsor: **Centre hospitalier de l'Université de Montréal (CHUM)** · enrollment: 80 (estimated)

## Conditions studied

- Prostate Cancer Metastatic

## Interventions

- **RADIATION:** Metastasis directed radiotherapy (MDRT)
- **OTHER:** no MDRT

## Key facts

- **NCT ID:** NCT05457699
- **Lead sponsor:** Centre hospitalier de l'Université de Montréal (CHUM)
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-30
- **Primary completion:** 2030-07-30
- **Final completion:** 2030-07-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05457699

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05457699, "Ablative Radiotherapy to Consolidate Maximal Systemic Response in Metastatic Prostate Cancer (ANCHOR-Prostate)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05457699. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*